Lyell Immunopharma Inc (NASDAQ: LYEL) kicked off on Friday, up 4.83% from the previous trading day, before settling in for the closing price of $0.58. Over the past 52 weeks, LYEL has traded in a range of $0.51-$3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 428.28% over the last five years. While this was happening, its average annual earnings per share was recorded 21.51%. With a float of $149.13 million, this company’s outstanding shares have now reached $256.56 million.
The firm has a total of 224 workers. Let’s measure their productivity. In terms of profitability, gross margin is -23680.95%, operating margin of -348844.44%, and the pretax margin is -323792.06%.
Lyell Immunopharma Inc (LYEL) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lyell Immunopharma Inc is 48.39%, while institutional ownership is 22.69%.
Lyell Immunopharma Inc (LYEL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.62% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Take a look at Lyell Immunopharma Inc’s (LYEL) current performance indicators. Last quarter, stock had a quick ratio of 13.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2970.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Analysing the last 5-days average volume posted by the [Lyell Immunopharma Inc, LYEL], we can find that recorded value of 2.15 million was better than the volume posted last year of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 53.13%. Additionally, its Average True Range was 0.05.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 9.25%, which indicates a significant decrease from 76.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.34% in the past 14 days, which was lower than the 94.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6543, while its 200-day Moving Average is $1.3826. Now, the first resistance to watch is $0.6275. This is followed by the second major resistance level at $0.6448. The third major resistance level sits at $0.6644. If the price goes on to break the first support level at $0.5906, it is likely to go to the next support level at $0.5710. Now, if the price goes above the second support level, the third support stands at $0.5537.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
The company with the Market Capitalisation of 178.25 million has total of 292,162K Shares Outstanding. Its annual sales at the moment are 130 K in contrast with the sum of -234,630 K annual income. Company’s last quarter sales were recorded 30 K and last quarter income was -44,580 K.
